AC
BMRN icon

AlphaCore Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaCore Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Sell
3,661
-512
-12% -$28K ﹤0.01% 1091
2026
Q1 		$236K Buy
+4,173
New +$243K 0.01% 779

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

AlphaCore Capital's BMRN Position: Q2 2026 in Review

AlphaCore Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q2 2026, selling an estimated $28K and leaving 3,661 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

AlphaCore Capital first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $236K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • AlphaCore Capital held 3,661 shares of BioMarin Pharmaceuticals worth $209K as of Q2 2026.
  • AlphaCore Capital sold 512 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $28K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1091 holding.
  • AlphaCore Capital first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • AlphaCore Capital's BioMarin Pharmaceuticals position peaked at $236K in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.